ANXA1在小细胞肺癌中的表达及临床意义

The expression and clinical significance of ANXA1 in small-cell lung cancer

目的:检测膜联蛋白A1(annexin A1,ANXA1)在小细胞肺癌(small-cell lung cancer,SCLC)组织中的表达水平,并探讨其临床意义。方法:采用实时荧光定量PCR法检测ANXA1 m RNA在102例SCLC组织、36例癌旁组织和66例正常肺组织中的表达水平,免疫组织化学法检测ANXA1蛋白在36例癌及癌旁组织中的表达情况,分析ANXA1 m RNA表达水平与SCLC患者临床病理特征及预后的关系。结果:无论在基因还是蛋白水平,ANXA1在SCLC组织中的表达水平较正常组织明显降低,差异具有统计学意义(P<0.01)。ANXA1的表达与疾病的分期、对化疗的敏感性及生存时间密切相关,差异均具有统计学意义(P值均<0.05)。高表达ANXA1患者的总生存和无进展生存优于低表达者,差异均具有统计学意义(P值均<0.001)。单因素和多因素方差分析发现,ANXA1可作为SCLC的独立预后指标。结论:ANXA1可能作为评估SCLC临床预后的潜在靶标。

Objective： To investigate the expression level of annexin in patients with small-cell lung cancer （SCLC）, and to clinical significance. A1 （ANXA1） explore its Methods： The expression levels of ANXA1 mRNA in 102 specimens of SCLC tissues, 36 specimens of para-carcinoma lung tissues and 66 specimens of normal lung tissues were detected by real-time fluorescent quantitative-PCR. The expression levels of ANXA1 protein in 36 specimens of SCLC tissues and the para-carcinoma lung tissues were detected by immunohistochemistry. The relationships of the expression level ofANXA1 mRNA with clinicopathological features and the prognosis of patients with SCLC were evaluated. Results： The expression levels of ANXA1 mRNA and protein in SCLC tissues were significantly decreased as compared with those in normal lung tissues （P 〈 0.01）. The expression of ANXA1 wascorrelated with clinical stage, chemosensitivity and overall survival （all P 〈 0.05）. Moreover, the overall survival and progression-free survival of SCLC patients with high expression of ANXAI were significantly improved （both P 〈 0.001）. Univariate and multivariate analyses revealed that ANXAI was an independent predictor of overall survival of SCLC patients. Conclusion： ANXA1 may become a potential prognostic factor of SCLC